A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest President Donald Trump has canceled the $35 insulin co-pay cap for certain Medicare programs.

President Donald Trump’s Day One executive order rescinding Biden-era Medicare and Medicaid price innovation programs signals sweeping changes to the drug and treatment pricing agency within the Centers for Medicare and Medicaid Services and perhaps a substantive shake-up in two of the largest federal social welfare programs.

President Donald Trump rescinded an executive order issued by former President Joe Biden aimed at finding new models for lowering drug costs. Trump's action didn't affect the caps on seniors' drug costs or Medicare price negotiations that Biden signed into law.

“Rescinding the cap on insulin at $35 only makes pharmaceutical richer and everyday Americans, including MAGA voters, seriously poorer,” Steven Bechloss—author of the Substack, America, America — posted to the Bluesky social media platform.

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle drug pricing reforms

Trump stopped a program that had been in the works and was intended to give Medicare recipients access to more than 100 generic drugs for $2 a month, according to another executive order signed on Trump's first day in his new term.

Amidst political shifts, President Trump revoked a Biden-era directive aimed at reducing prescription drug costs, raising questions about future policies. Under Biden's order, the Department of Health and Human Services (HHS) was tasked with exploring ways to cut medication expenses for Medicare and Medicaid,